Published: 13 May 2026
Stable ASA.P® formulation confirmed after 12 months
12 months of documented stability strengthens the development of ASA.P®
Auxesis Pharma has now reached one of the most important milestones in the development of the drug candidate ASA.P®: a stable formulation that has continued to demonstrate very strong stability and quality following 12 months of stability studies.
This marks a significant step forward in the company’s continued development and strengthens the foundation for upcoming clinical and regulatory steps.
12 months of stability – a strong result
ASA.P® is based on an advanced formulation in which acetylsalicylic acid, ASA, is kept stable in liquid form over time — something that has historically been a major technical challenge.
Following 12 months of stability studies, the formulation has continued to demonstrate very strong stability and quality, with very low degradation at both room temperature and elevated temperatures.
The results are in line with previous forecasts and further strengthen confidence in the technology behind ASA.P®.
This type of stability is a highly important factor in pharmaceutical development and forms a central foundation for continued clinical and regulatory development.
An important step forward
The positive results from the stability study strengthen Auxesis Pharma’s continued development work and mark another important step in the company’s long-term work with ASA.P®.
The company now continues development according to plan, with a focus on regulatory processes, clinical studies and continued technological development.